DM21

DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936[1].

Product Specifications

CAS Number

[2243689-80-5]

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

Drug-Linker Conjugates for ADC; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dm21.html

Purity

99.34

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(CCCCCSCNC([C@H](C)NC([C@@H](C)NC([C@H](C)NC(CCCCCN5C(C=CC5=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1

Molecular Formula

C58H83ClN8O16S

Molecular Weight

1215.84

Precautions

H302, H315, H319, H335

References & Citations

[1]Olga Ab, et al. Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models Free. Cancer Res (2021) 81 (13_Supplement) : 1841.